Descrizione Clinica
IRIREACT 3 MG/ML + 0.5 MG/ML COLLIRIAR, SOLUTION IN MONODOSE CONTENT
active ingredients
100 ml of solution contain: Active ingredients: Feniramina maleate 0,30 g; Tetrizolina hydrochloride 0.05 g. For the full list of excipients, see paragraph 6.1.Excellent
Boric acid; Borace; Water for injectable preparations.Therapeutic indications
IRIREACT is indicated in the treatment of allergic and inflammatory conditions of the joint accompanied by photophobia, tearing, feeling of foreign body, pain.Contraindications
Hypersensitivity to the components of the product or other substances closely related to the chemical; in particular towards xilometazolina, oximetazolina, nafazolina. Glaucoma at a narrow/closed angle or other severe eye diseases. Contraindicated in children under 12 years. Generally contraindicated during pregnancy and nursing (see paragraph 4.6). Contraindicated in the contemporary treatment with inhibiting drugs of monoaminoxydase (tranilcipromine, fenelzina, pargilina) (see paragraph 4.5).Population
Posology 1-2 drops to be instilled in the affected eye 2-3 times a day. Do not exceed the recommended doses. Strictly stick to the recommended doses. A higher dose of the product even if taken in a topical way and for a short period of time can give rise to serious systemic effects. IRIREACT is contraindicated in children under 12 years of age. (see paragraph 4.3).Conservation
Store at temperature not exceeding 30 ° C.Warnings
The product, while presenting a very low systemic absorption, must be used with caution in subjects suffering from hypertension, hyperthyroidism, heart disorders, and hyperglycemia (diabetes). In case of persisting or aggravating symptoms after a short period of treatment invite the patient to consult the doctor. In any case, the product should not be used for more than 4 consecutive days, except for a different prescription, given the possibility that they may occur otherwise, side effects. The product, if accidentally ingested or used for long periods at excessive doses, can determine toxic phenomena. Infections, pus, foreign bodies in the eye, mechanical, chemical, heat damage, require medical intervention. Prolonged use of topical products can lead to awareness-raising. In this case it is necessary to stop treatment and establish suitable therapy.Interactions
IRIREACT should not be used in conjunction with the inhibition of monoaminoxydase drugs, since this can lead to severe hypertensive crisis.Effects
The use of the product can sometimes determine pupilal dilation, systemic effects from absorption (hypertension, heart disorders, hyperglycemia), increased blood pressure, nausea, headache. In children if accidentally ingested, the preparation can determine even deep sopore, and hypotonia. Rarely, phenomena of hypersensitivity can occur. In this case it is necessary to stop the treatment and establish suitable therapy. Reporting of suspicious adverse reactions The reporting of suspicious adverse reactions that occur after the authorization of the medicinal product is important, as it allows continuous monitoring of the benefit/risk of the medicinal product. Healthcare workers are required to report any suspected adverse reaction via the national reporting system at the address www.aifa.gov.it/content/segnalazioni-reazioni-avverse.Overdosing
The product, if accidentally ingested or used for a long period at excessive doses, can determine toxic phenomena. Accidental ingestion of the drug, especially in children, can cause depression of the central nervous system: sedation marked (strong drowsiness), coma. If this happens, use gastric lavender and general support measures.Data relating to the use of maleate phenyramine and tetrizoline hydrochloride in pregnant women do not exist or are in limited number. For precautionary purposes, it is preferable during pregnancy and during breastfeeding, use IRIREACT only in case of actual need, under the direct control of the doctor.
Source: Farmadati
